Ann: FY22 Results Commentary, page-3

Be careful, DNA has a long history of "next monday" it'll all be good and promising starts to the period. They may have lucked out on the win rate in July, who knows. I certainly wouldn't be annualising anything.

On the plus side, the vendor won't get his 25% on DSV EBITDA over USD16m unless, well, it makes USD16m+.

Massive current deficit even backing out the vendor loan. Let's hope they can sort that out, because with that vendor loan and the lack of rental payments hanging over it, DNA is uninvestable.

And thats assuming you don't care about how we got here and who is running this now, which one probably should.